EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Targeting integrins in drug‐resistant acute myeloid leukaemia

Heather A Ogana iD, Samantha Hurwitz, Nathan Wei, Eliana Lee, Kayla Morris, Karina Parikh, Yong-Mi Kim

British Journal of Pharmacology · 2024

DOI: 10.1111/bph.16149 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, 2024. Written by Heather A Ogana and 6 co-authors. Institution: Children's Hospital Los Angeles, Department of Pediatrics, Division of Hematology and Oncology, Cancer and Blood Disease Institute, Keck School of Me…. Major MEDLINE topics: Integrins, Leukemia, Myeloid, Acute. Cited 30 times so far (Crossref); 163 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Acute myeloid leukaemia (AML) continues to have a poor prognosis, warranting new therapeutic strategies. The bone marrow (BM) microenvironment consists of niches that interact with not only normal haematopoietic stem cells (HSC) but also leukaemia cells like AML. There are many adhesion molecules in the BM microenvironment; therein, integrins have been of central interest. AML cells express integrins that bind to ligands in the microenvironment, enabling adhesion of leukaemia cells in the microenvironment, thereby initiating intracellular signalling pathways that are associated with cell migration, cell proliferation, survival, and drug resistance that has been described to mediate cell adhesion‐mediated drug resistance (CAM‐DR). Identifying and targeting integrins in AML to interrupt interactions with the microenvironment have been pursued as a strategy to overcome CAM‐DR. Here, we focus on the BM microenvironment and review the role of integrins in CAM‐DR of AML and discuss integrin‐targeting strategies. LINKED ARTICLES This article is part of a themed issue on Cancer Microenvironment and Pharmacological Interventions. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.2/issuetoc

Subjects

MeSH terms (MEDLINE)

IntegrinsLeukemia, Myeloid, AcuteHumansBone MarrowHematopoietic Stem CellsCell Adhesion MoleculesTumor Microenvironment

Author keywords

acute myeloid leukaemiabone marrow microenvironmentcell adhesion moleculescell adhesion-mediated chemoresistanceintegrinsleukaemia stem cellstherapy

Substances

IntegrinsCell Adhesion Molecules

Authors and institutions

  • Children's Hospital Los Angeles, Department of Pediatrics, Division of Hematology and Oncology, Cancer and Blood Disease Institute, Keck School of Medicine, University of Southern California, Los Angeles, California, US…

ORCID profiles: Heather A Ogana

Funding

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Cite

APA

Ogana, H. A., Hurwitz, S., Wei, N., Lee, E., Morris, K., Parikh, K., & Kim, Y. M. (2024). Targeting integrins in drug‐resistant acute myeloid leukaemia. British Journal of Pharmacology. https://doi.org/10.1111/bph.16149

Vancouver

Ogana HA, Hurwitz S, Wei N, Lee E, Morris K, Parikh K, et al. Targeting integrins in drug‐resistant acute myeloid leukaemia. British Journal of Pharmacology. 2024. doi:10.1111/bph.16149

BibTeX
@article{Ogana2024,
  author = {Ogana, Heather A and Hurwitz, Samantha and Wei, Nathan and Lee, Eliana and Morris, Kayla and Parikh, Karina and Kim, Yong-Mi},
  title = {Targeting integrins in drug‐resistant acute myeloid leukaemia},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.16149}
}
Start for free →